• CSPC received a USD 10 million milestone payment from AstraZeneca on Aug. 5, 2026 under their strategic research collaboration.
• Payment followed AstraZeneca’s exercise of a license option for one preclinical candidate program.
• Collaboration covers discovery of oral small-molecule preclinical candidates across multiple targets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260805-12273585), on August 05, 2026, and is solely responsible for the information contained therein.